Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($13.26); post-transaction worth based connected April 13, 2026 marketplace adjacent ($14.13).

• How does this transaction subordinate to Rubinstein’s caller trading pattern?
  Rubinstein has executed respective similar-sized nonstop income successful the past month, with caller transactions reflecting a cadence shaped by reduced disposable stock capableness arsenic nonstop holdings person declined by 19.4% since mid-March 2026.

• What was the mechanics of the transaction regarding derivatives?
  This lawsuit progressive the workout of 44,166 vested options crossed 4 tranches, followed by the merchantability of 57,180 communal shares — a higher fig that reflects income from some recently exercised options and pre-existing straight held shares.

• How worldly is the merchantability successful the discourse of ongoing ownership?
  The merchantability accounted for 11.95% of Rubinstein’s nonstop Common Stock position, but she maintains a important equity involvement done 421,174 straight held shares and 192,936 further banal options that stay exercisable.

• What is the accusation of remaining enactment holdings?
  With 192,936 options inactive outstanding, Rubinstein retains a meaningful equity involvement beyond her nonstop stock holdings.

* 1-year terms alteration calculated utilizing April 13th, 2026 arsenic the notation date.

• ADPT’s halfway offerings see immunoSEQ (immunosequencing for probe and diagnostics), clonoSEQ (minimal residual illness detection successful hematologic cancers), and T-Detect COVID, with further products and services targeting immune-driven illness diagnostics and monitoring.

• Adaptive Biotechnologies Corp. generates gross done the merchantability of objective diagnostic tests, probe services, and strategical collaborations with partners successful biopharma and exertion sectors.

• Primary customers see beingness sciences researchers, objective laboratories, pharmaceutical companies, and healthcare providers focused connected oncology, infectious disease, and autoimmune conditions.